Three-drug combo targets immune suppression to overcome melanoma resistance

For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment options remain frustratingly limited. A new study from Vanderbilt researchers led by Professor Emerita of Pharmacology Ann…

Continue Reading

News Source: medicalxpress.com